Ned Pagliarulo

@NedPagliarulo

Senior editor @ BioPharma Dive

Washington, DC
Vrijeme pridruživanja: prosinac 2012.

Tweetovi

Blokirali ste korisnika/cu @NedPagliarulo

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @NedPagliarulo

  1. proslijedio/la je Tweet
    prije 17 sati
    Poništi
  2. proslijedio/la je Tweet
    prije 18 sati

    Btw, that now 24% stock increase equates to more than $12B in added value to 's market cap.

    Poništi
  3. prije 19 sati

    PTAB decision on Tecfidera challenge +23%

    Poništi
  4. prije 23 sata

    An aspect of coronavirus-related disruption that I hadn't thought of:

    Poništi
  5. proslijedio/la je Tweet
    5. velj

    Dems are now chanting HR 3 — their drug pricing bill. Trump is trying to talk over them

    Poništi
  6. proslijedio/la je Tweet

    on call: No knowledge of additional responses to remdesivir. Waiting for clinical data. On manufacturing capacity: “We are investing heavily to be prepared as best we can.”

    Poništi
  7. proslijedio/la je Tweet
    4. velj

    FDA issued an Emergency Use Authorization to authorize the emergency use of CDC's 2019-Novel Coronavirus (2019-nCoV) Real-Time Reverse Transcriptase (RT)-PCR Diagnostic Panel

    Poništi
  8. 4. velj

    Semi regular reminder that has ~$26 billion in cash and marketable securities

    Prikaži ovu nit
    Poništi
  9. 4. velj

    Impairment charge took on Kite assets tied to treatment of indolent NHL, whereas in 2018 it was related to a specific asset, the anti-BCMA product KTE-585:

    Prikaži ovu nit
    Poništi
  10. 4. velj
    Prikaži ovu nit
    Poništi
  11. 4. velj

    recorded impairment charge of $800M related to R&D acquired in its deal for Kite Pharma. Last Q4 it took a $820M impairment charge.

    Prikaži ovu nit
    Poništi
  12. 4. velj

    What's $100 million between friends?

    Poništi
  13. proslijedio/la je Tweet

    The safety of the nation’s blood supply is a top FDA priority. We’ve received questions about the potential impact of the novel coronavirus (2019-nCoV) on blood safety. Respiratory viruses are generally not known to be transmitted via blood transfusion.

    Prikaži ovu nit
    Poništi
  14. proslijedio/la je Tweet
    4. velj

    a16z's growth in biotech/healthcare investing: 2015: $200m fund + hire Vijay Ponde 2017: $450m fund + add 2019: Add Julie Yoo as GP 2020: $750m fund + add Here's what the Bio Fund 3 team is targeting:

    Poništi
  15. 4. velj

    HHS expanding partnership with to develop multiple antibodies against 2019-nCoV, acc. to statement from agency this morning. No mention of funding commitment.

    Poništi
  16. proslijedio/la je Tweet
    3. velj

    Whoa, that NEJM report from Germany claiming asymptomatic transmission of turned out to be wrong The index patient did have symptoms while in Germany. German RKI has written a letter to NEJM to set the record straight

    Poništi
  17. 3. velj

    Instructive - and good - read on the ripple effects of drugmakers rushing in to offer up compounds with unproven efficacy in a viral outbreak:

    Poništi
  18. 3. velj

    announcing tonight it's making its adjuvant technology available to groups working w/ CEPI to develop a coronavirus vaccine. Univ. of Queensland the first to formalize an agreement, GSK says. + NIH, CureVac and Inovio the other 3 groups working with CEPI.

    Poništi
  19. proslijedio/la je Tweet
    1. velj

    Everyone interested in that /HIV preprint should read this debunking piece It's unfortunate this sloppy work was widely spread and adding fuel to bioweapon conspiracy theories even though it may never pass peer-review in any serious journal...

    Poništi
  20. 31. sij

    sets Palforzia price at $890/month or just over $10,000 a year. Right in the middle of the $3K to $20K range the company was guiding toward in run-up to approval decision.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·